Form 4: Director Deborah Dunsire Receives Ultragenyx Equity Grant

Director Deborah Dunsire acquired 7,751 restricted stock units and 14,058 stock options as part of an annual incentive plan.

Summary

• Director Deborah Dunsire was granted 7,751 Restricted Stock Units (RSUs) on May 14, 2026.
• Director Dunsire was granted 14,058 stock options with an exercise price of $25.80.
• Both the RSUs and the stock options vest on the earlier of the next Annual Meeting of Stockholders or May 14, 2027.
• Following these transactions, the director's total beneficial ownership of common stock increased to 38,566 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which carries neutral sentiment for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standardized vesting schedule tied to annual meeting cycles.

Negatives

• Dilutive impact of new equity grants on existing shareholders, though typical for corporate governance.

Risks

• Market volatility affecting the value of the granted options.
• Potential for future dilution if additional equity incentive plans are authorized.

Future Outlook

The equity grants are subject to standard vesting conditions, aligning the director's tenure with the company's performance through May 2027.

Management Comments

• The awards were issued under the Company's 2023 Incentive Plan.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of RSU and option combinations is consistent with compensation structures at mid-cap biopharmaceutical companies.
• Vesting periods of one year for director equity are standard practice among peer companies in the RARE disease space.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of equity awards on the earlier of the next Annual Meeting or May 14, 2027.

Key Dates

Keywords

Ultragenyx, RARE, Form 4, Insider Trading, Equity Compensation, Director Compensation